- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04593810
Effect of Automated Closed-Loop Ventilation Versus Conventional Ventilation on Duration and Quality of Ventilation (ACTiVE)
Effect of Automated Closed-Loop Ventilation Versus Conventional Ventilation on Duration and Quality of Ventilation ('ACTiVE') - a Randomized Clinical Trial in Intensive Care Unit Patients
INTELLiVENT-Adaptive Support Ventilation (ASV) is a fully automated closed-loop mode of mechanical ventilation available on commercial ventilators. Evidence for clinical benefit of INTELLiVENT-ASV in comparison to non-automated ventilation is lacking.
The ACTiVE study is an international, multicenter, randomized controlled trial in invasively ventilated ICU patients with the objective to compare INTELLiVENT-ASV to conventional ventilation. We hypothesise that INTELLiVENT-ASV shortens the duration of ventilation. The secondary hypothesis is that INTELLiVENT-ASV improves the quality of breathing.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective
The primary objective of this trial is to compare INTELLiVENT-ASV with non-automated ventilation in critically ill intensive care unit (ICU) patients with respect to ventilation duration. One secondary aim is to test whether INTELLiVENT-ASV improves quality of breathing, expressed as the proportion of breath within lung-protective margins, in a time frame of 24 hours early after start of invasive ventilation.
Study design
International, multicenter, superiority randomized clinical trial in critically ill, intubated and ventilated adult ICU patients with an anticipated duration of ventilation of at least 24 hours.
Study population
Adult patients admitted to ICUs in the Netherlands and Italy.
Sample size calculation
The sample size is based on the hypothesis that INTELLiVENT-ASV will shorten ventilation duration by 1.5 days with no changes in mortality rate. Based on previously performed studies a sample of 1,200 patients (600 in each treatment group) is needed to have beta of 80% power and a two-tailed alpha of 0.05, to detect a mean between-group difference of 1.5 VFD-28, allowing a dropout rate of 5%. By including 1,200 patients, this study will be sufficiently powered to detect differences in the secondary endpoint, which is quality of breathing.
Methods:
Within one hour of start of ventilation in the ICU, patients are randomly assigned in a 1:1 ratio to INTELLiVENT-ASV or non-automated ventilation. Randomization will be stratified by center. As soon as possible after randomization, but within a maximum of 72 hours, deferred consent is obtained from the legal representative of the patient.
INTELLiVENT-ASV In patients who are randomized to INTELLiVENT-ASV, the ventilator is switched to this fully automated mode as soon possible. The sensors for end-tidal carbon dioxide (ETCO2) and pulse oximetry (SpO2) are connected and activated in the ventilator. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable. If needed, the targets zones for ETCO2 and SpO2 are adjusted. The default alarm limits are accepted.
It is advised to enable QuickWean in all patients. The use of the automated Spontaneous Breathing Trial (SBT) function is left to the discretion of the clinician.
CONVENTIONAL VENTILATION Patients who are randomized to conventional ventilation will be ventilated with a mode that is not fully automated, thus standard volume controlled (VCV) or pressure controlled ventilation (PCV), and pressure support ventilation (PSV), depending on patient's activity. None of the following semi or fully automated modes of ventilation is allowed at any time: Neurally Adjusted Ventilatory Assist (NAVA), SmartCare/PS, Proportional Assist Ventilation (PAV), or the predecessor of INTELLiVENT-ASV named ASV.
In all patients who receive assist ventilation (i.e., VCV or PCV), three times a day it should be checked whether the patient can accept supported ventilation (i.e., PSV); this should also be tried when the patient shows respiratory muscle activity during assist ventilation, or in case of patient-ventilator asynchrony.
Patients can be subjected to SBTs using either a T-piece or ventilation with minimal support (pressure support level < 10 cm H2O). An SBT is deemed successful when the following criteria are met for at least 30 minutes, i.e., respiratory rate < 35/min, peripheral oxygen saturation > 90%, increase < 20% of heart rate and blood pressure, and no signs of anxiety and diaphoresis.
In both groups patients are extubated if standard extubation criteria are fulfilled, i.e., normal body temperature, patient awake and responsive/cooperative, adequate cough reflex, adequate oxygenation, hemodynamically stable, and adequate lung function.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Michela Botta, MD
- Phone Number: +31626198315
- Email: m.botta@amsterdamumc.nl
Study Contact Backup
- Name: Anissa M Tsonas, MD
- Phone Number: +31614927716
- Email: a.m.tsonas@amsterdamumc.nl
Study Locations
-
-
-
Genua, Italy
- Not yet recruiting
- Ospedale Policlinico San Martino
-
Principal Investigator:
- Paolo Pelosi
-
Pavia, Italy
- Not yet recruiting
- Policlinico San Matteo Fondazione IRCCS
-
Principal Investigator:
- Francesco Mojoli
-
-
-
-
-
Almere, Netherlands
- Not yet recruiting
- Flevoziekenhuis
-
Amsterdam, Netherlands
- Recruiting
- Academic Medical Center, Intensive Care
-
Contact:
- Janneke Horn, MD, PhD
- Email: j.horn@amsterdamumc.nl
-
Delft, Netherlands
- Recruiting
- Reinier de Graaf Gasthuis
-
Contact:
- Pim LJ van der Heiden, MD PhD
- Email: Pim.vanderHeiden@rdgg.nl
-
Contact:
- Laura A Buiteman-Kruizinga
- Email: L.Kruizinga@rdgg.nl
-
Eindhoven, Netherlands
- Not yet recruiting
- Catharina Ziekenhuis
-
Leiden, Netherlands
- Not yet recruiting
- Leiden UMC
-
Nijmegen, Netherlands
- Not yet recruiting
- Canisius-Wilhelmina Hospital
-
Tilburg, Netherlands
- Not yet recruiting
- Elisabeth-TweeSteden Ziekenhuis
-
Utrecht, Netherlands
- Not yet recruiting
- Diakonessenhuis, Utrecht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- admission to one of the participating ICUs
- intubated and receiving invasive ventilation
- anticipated duration of ventilation of at least 24 hours
Exclusion Criteria:
- age below 18 years
- patients with suspected or confirmed pregnancy
- invasive ventilation > 1 hour in the ICU
- invasive ventilation > 6 hours directly preceding the current ICU admission
- participation in another interventional trial using similar endpoints
- after recent pneumectomy or lobectomy
- morbid obesity (body mass index > 40 kg/m2)
- premorbid restrictive pulmonary disease
- unreliable pulse oximetry (secondary to carbon monoxide poisoning or sickle cell disease)
- any neurologic diagnosis that can prolong duration of mechanical ventilation, e.g., Guillain-Barré syndrome, high spinal cord lesion or amyotrophic lateral sclerosis, multiple sclerosis, or myasthenia gravis
- patients receiving or planned to receive veno-venous, veno-arterial or arterio-venous extracorporeal membrane oxygenation (ECMO)
- unavailability of INTELLiVENT-ASV (no ventilator available with this ventilation mode)
- previously randomized in this study
- no informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INTELLiVENT-ASV
Use of INTELLIVENT-ASV after intubation and during all mechanical ventilation in the ICU.
|
INTELLiVENT-ASV is activated as soon possible.
The sensors for ETCO2 and SpO2 are connected and activated.
Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.
|
Active Comparator: Conventional ventilation
Use of conventional ventilation after intubation and during all mechanical ventilation in the ICU.
|
Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity.
None of the semi or fully automated modes of ventilation is allowed at any time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventilator-free days and alive at day 28
Time Frame: first 28 days after start of ventilation
|
The number of days from day 1 to day 28 the patient is alive and breathes without assistance of the mechanical ventilator, if the period of unassisted breathing lasted at least 24 consecutive hours
|
first 28 days after start of ventilation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of ventilation
Time Frame: first 28 days after start of ventilation
|
Duration of ventilation in survivors
|
first 28 days after start of ventilation
|
Quality of breathing
Time Frame: 24 hours early after start of invasive ventilation.
|
Proportion of breaths within lung-protective margins
|
24 hours early after start of invasive ventilation.
|
Length of stay
Time Frame: first 90 days after start of ventilation
|
Length of stay in the intensive care unit and in the hospital
|
first 90 days after start of ventilation
|
Mortality
Time Frame: first 90 days after start of ventilation
|
Any death during ICU- or hospital-stay, at day 28 and day 90
|
first 90 days after start of ventilation
|
Pulmonary complications
Time Frame: daily until ICU discharge or day 28
|
Development of ARDS, severe hypoxemia, severe hypercapnia, severe atelectasis, pneumothorax and ventilator-associated pneumonia
|
daily until ICU discharge or day 28
|
Rescue therapies for severe hypoxemia or severe atelectasis
Time Frame: daily until ICU discharge or day 28
|
Incidence of use of rescue therapies for severe hypoxemia or severe atelectasis: recruitment maneuver, prone positioning, bronchoscopy for opening atelectasis
|
daily until ICU discharge or day 28
|
Extubation failure
Time Frame: daily until ICU discharge or day 28
|
Extubation with need for reintubation within 24 hours
|
daily until ICU discharge or day 28
|
Maximal inspiratory pressure (MIP)
Time Frame: within 24 hours after extubation
|
Maximal inspiratory pressure measured after extubation at centers that can collect this data
|
within 24 hours after extubation
|
Quality of Life questionnaire
Time Frame: day 28 after start of ventilation
|
The European Quality of life 5 Dimensions 5 Levels questionnaire (EQ-5D-5L) is used to assess health-related quality of life status in adults.
It consists of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels (from 1 to 5) that are described by statements appropriate to that dimension.
Higher values mean worse quality of life.
The evaluation includes a visual analogue scale to quantitative measure the overall health status.
This scale has a range from 0 to 100.
|
day 28 after start of ventilation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Janneke Horn, MD, PhD, Department of Intensive Care, Academic Medical Center
- Study Director: Frederique Paulus, PhD, Department of Intensive Care, Academic Medical Center
- Study Director: Marcus J Schultz, MD,PhD, Department of Intensive Care, Academic Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACTiVE (Nationwide Children's Hospital Intramural Grant - 292913)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventilator-free Days
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Amsterdam UMC, location VUmc; Leiden University Medical Center; Gelre Hospitals; Tergooi Hospital and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingThe Number of Ventilator-free Days in the 28 Days Following LTFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingFluid Overload | Mechanical Ventilation | Deresuscitation | Ventilator-free DaysNetherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Maastricht University Medical Center; Amsterdam UMC, location VUmc; St. Antonius... and other collaboratorsCompletedVentilator-free DaysNetherlands
-
National Institute on Drug Abuse (NIDA)TerminatedPlacebo | Daily Oral Pexacerfont for 28 Days (300 mg/Day Loading Dose for 7 Days, FollowedUnited States
-
California Pacific Medical Center Research InstituteCompletedIntensive Care Unit DaysUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedPregnant Woman With Twins After 22 Weeks 0 Days of GestationFrance
-
NestléCompletedFocus of Study is Healthy Chinese Lactating Mother 0-270 DaysChina
-
University of California, Los AngelesWithdrawn7-dose Control - Progressive Muscle Relaxation Only | 5-dose - Pairs Progressive Muscle Relaxation With Fruit 5 Consecutive Days | 7-dose - Pairs Progressive Muscle Relaxation With Fruit 7 Consecutive Days | 9-dose - Pairs Progressive Muscle Relaxation With Fruit 9 Consecutive Days
-
Peking University People's HospitalUnknown
Clinical Trials on INTELLiVENT-ASV
-
Izmir Dr Suat Seren Chest Diseases and Surgery...CompletedChronic Obstructive Pulmonary DiseaseTurkey
-
Medical University of ViennaNot yet recruitingVentilator Lung
-
Izmir Dr Suat Seren Chest Diseases and Surgery...Completed
-
Hopital of MelunCompletedCritical Ill Patients | Ventilated PatientsFrance
-
Catharina Ziekenhuis EindhovenAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)CompletedPostoperative Care | Intensive Care Units | Ventilators, MechanicalNetherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University of Zurich; Dijklander Ziekenhuis; Reinier de Graaf GroepCompletedMechanical Ventilation | Mechanical PowerNetherlands
-
Northern State Medical UniversityCompletedMechanical Ventilation Complication | Postoperative Pulmonary AtelectasisRussian Federation
-
University of ZurichCompletedAcute Respiratory Distress Syndrome | Cardiogenic Shock
-
Centre Hospitalier Intercommunal de Toulon La Seyne...CompletedIntensive Care Patients Invasively VentilatedFrance, Italy
-
Cliniques universitaires Saint-Luc- Université...CompletedAcute Mechanical Ventilatory Failure | Psychosis Associated With Intensive CareBelgium